Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TCON Stock Summary
Top 10 Correlated ETFs
TCON
In the News

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Edward White - H.C. Wainwright & Co., LLC Joel Beatty - Robert W.

Why Is TRACON Pharma (TCON) Stock Down 51% Today?
TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab (NASDAQ: IMAB ). The bad news for TCON stock comes from a legal ruling favoring I-Mab.

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade
Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Soumit Roy - Jones Research Joel Beatty - Robert W. Baird & Co. Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call.

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Revisiting Tracon Pharmaceuticals
Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors.

TRACON Pharmaceuticals doses first patient in drug trial to treat malignant tumours
TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin, in front line therapy of patients with malignant tumours. The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma sub-types of leiomyosarcoma and dedifferentiated liposarcoma, according to TRACON.

TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. Edward White - H.C.
TCON Financial details
TCON Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 1.11 | 0 | 0 | 0.02 | 0 | |
Net income per share | -12.97 | -7.46 | -1.87 | -1.67 | -1.4 | |
Operating cash flow per share | -11.42 | -7.79 | -1.9 | -1.31 | -1.25 | |
Free cash flow per share | -11.42 | -7.79 | -1.9 | -1.31 | -1.26 | |
Cash per share | 14.51 | 5.41 | 4.02 | 1.4 | 0.83 | |
Book value per share | 7.96 | 0.89 | 2.79 | 0.68 | -0.34 | |
Tangible book value per share | 7.96 | 0.89 | 2.79 | 0.68 | -0.34 | |
Share holders equity per share | 7.96 | 0.89 | 2.79 | 0.68 | -0.34 | |
Interest debt per share | 2.47 | 1.89 | 0.56 | 0.11 | 0.52 | |
Market cap | 16.98M | 7.1M | 105.11M | 47.79M | 31.17M | |
Enterprise value | -1.73M | -3.97M | 77.51M | 25.26M | 23.54M | |
P/E ratio | -0.49 | -0.31 | -6.26 | -1.66 | -1.06 | |
Price to sales ratio | 5.66 | 0 | 0 | 138.12 | 0 | |
POCF ratio | -0.55 | -0.3 | -6.17 | -2.12 | -1.19 | |
PFCF ratio | -0.55 | -0.3 | -6.17 | -2.11 | -1.19 | |
P/B Ratio | 0.79 | 2.63 | 4.19 | 4.08 | -4.36 | |
PTB ratio | 0.79 | 2.63 | 4.19 | 4.08 | -4.36 | |
EV to sales | -0.58 | 0 | 0 | 72.99 | 0 | |
Enterprise value over EBITDA | 0.05 | 0.18 | -4.78 | -0.89 | -0.84 | |
EV to operating cash flow | 0.06 | 0.17 | -4.55 | -1.12 | -0.9 | |
EV to free cash flow | 0.06 | 0.17 | -4.55 | -1.12 | -0.9 | |
Earnings yield | -2.06 | -3.19 | -0.16 | -0.6 | -0.94 | |
Free cash flow yield | -1.81 | -3.33 | -0.16 | -0.47 | -0.84 | |
Debt to equity | 0.9 | 5.72 | 0.49 | 1.27 | -3.72 | |
Debt to assets | 0.47 | 0.85 | 0.33 | 0.56 | 1.37 | |
Net debt to EBITDA | 0.54 | 0.5 | 1.7 | 0.79 | 0.27 | |
Current ratio | 3.01 | 1.46 | 3.5 | 1.82 | 0.81 | |
Interest coverage | -150.39 | -57.76 | -29.77 | -89.14 | -28.06 | |
Income quality | 0.88 | 1.04 | 1.02 | 0.79 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.43 | 0 | 0 | 50.71 | 0 | |
Research and developement to revenue | 10.15 | 0 | 0 | 32.21 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.14 | 0 | |
Capex to depreciation | 0 | 0 | 0.38 | 0.81 | -0.24 | |
Stock based compensation to revenue | 0.89 | 0 | 0 | 5.13 | 0 | |
Graham number | 48.2 | 12.22 | 10.83 | 5.04 | 3.28 | |
ROIC | 3.61 | 1.51 | 0.57 | 1.07 | 1.45 | |
Return on tangible assets | -0.86 | -1.25 | -0.45 | -1.08 | -1.51 | |
Graham Net | 7.38 | 0.33 | 2.65 | 0.53 | -0.44 | |
Working capital | 27.11M | 5.43M | 26.37M | 11.26M | -4.14M | |
Tangible asset value | 21.44M | 2.7M | 25.07M | 11.71M | -7.15M | |
Net current asset value | 21.4M | 1.84M | 24.55M | 10.09M | -8.39M | |
Invested capital | 0.3 | 1.98 | 0.18 | 0.13 | -1.37 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 862.5K | 3.33M | 4.43M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.63 | -8.4 | -0.67 | -2.45 | 4.1 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.48 | -0.31 | -0.3 | -0.32 | -0.46 | |
Operating cash flow per share | -0.34 | -0.4 | -0.32 | -0.21 | -0.21 | |
Free cash flow per share | -0.34 | -0.4 | -0.32 | -0.21 | -0.21 | |
Cash per share | 0.85 | 0.67 | 0.79 | 0.78 | 0.28 | |
Book value per share | 0.14 | 0.13 | -0.12 | -0.32 | -0.47 | |
Tangible book value per share | 0.14 | 0.13 | -0.12 | -0.32 | -0.47 | |
Share holders equity per share | 0.14 | 0.13 | -0.12 | -0.32 | -0.47 | |
Interest debt per share | 0.04 | 0 | 0.43 | 0.48 | 0.05 | |
Market cap | 51.57M | 40.54M | 35.85M | 33.22M | 44.8M | |
Enterprise value | 35.63M | 26.96M | 27.91M | 25.59M | 38.19M | |
P/E ratio | -1.36 | -1.63 | -1.38 | -1.15 | -1.03 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -7.65 | -5.06 | -5.25 | -7.14 | -8.95 | |
PFCF ratio | -7.64 | -5.06 | -5.25 | -7.13 | -8.95 | |
P/B Ratio | 18.48 | 15.95 | -13.61 | -4.65 | -4.05 | |
PTB ratio | 18.48 | 15.95 | -13.61 | -4.65 | -4.05 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.77 | -4.34 | -4.42 | -4.39 | -5.23 | |
EV to operating cash flow | -5.28 | -3.36 | -4.09 | -5.5 | -7.63 | |
EV to free cash flow | -5.28 | -3.36 | -4.08 | -5.5 | -7.63 | |
Earnings yield | -0.18 | -0.15 | -0.18 | -0.22 | -0.24 | |
Free cash flow yield | -0.13 | -0.2 | -0.19 | -0.14 | -0.11 | |
Debt to equity | 5.76 | 5.17 | -8.46 | -3.72 | -1.75 | |
Debt to assets | 0.85 | 0.84 | 1.13 | 1.37 | 2.33 | |
Net debt to EBITDA | 1.69 | 2.19 | 1.26 | 1.31 | 0.9 | |
Current ratio | 1.16 | 1.17 | 1.53 | 0.81 | 0.5 | |
Interest coverage | -363.31 | -779.88 | -109.95 | -6.35 | -6.16 | |
Income quality | 0.71 | 1.29 | 1.06 | 0.66 | 0.59 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0.15 | -0.08 | -0.11 | -0.36 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.25 | 0.93 | 0.91 | 1.53 | 2.2 | |
ROIC | 0.66 | 0.28 | 0.45 | 0.31 | 1.91 | |
Return on tangible assets | -0.5 | -0.4 | -0.33 | -0.37 | -1.31 | |
Graham Net | 0.03 | 0.02 | -0.25 | -0.41 | -0.54 | |
Working capital | 2.34M | 2.09M | 6.26M | -4.14M | -7.04M | |
Tangible asset value | 2.79M | 2.54M | -2.64M | -7.15M | -11.07M | |
Net current asset value | 1.22M | 1.02M | -4.28M | -8.39M | -12.26M | |
Invested capital | 0.25 | 0 | -3.45 | -1.37 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.47M | 5.5M | 5.5M | 1.96M | 1.96M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -3.41 | -2.44 | 2.46 | 1.01 | 0.98 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
TCON Frequently Asked Questions
What is TRACON Pharmaceuticals, Inc. stock symbol ?
TRACON Pharmaceuticals, Inc. is a US stock , located in San diego of Ca and trading under the symbol TCON
What is TRACON Pharmaceuticals, Inc. stock quote today ?
TRACON Pharmaceuticals, Inc. stock price is $0.6025 today.
Is TRACON Pharmaceuticals, Inc. stock public?
Yes, TRACON Pharmaceuticals, Inc. is a publicly traded company.